11.05.26 -- When To Build Out Your ClinOps Team — And Other Advice For First-Time Biotechs

Sponsors depend on sites to recruit patients, execute protocols, and collect high-quality data. In this candid panel discussion, we explore what makes sites want to work with a sponsor.

Rethink vendor evaluation by looking beyond indication experience to discover how cross-trial adaptability, proactive risk management, and team judgment drive true clinical trial resilience.

Evaluate CRO data governance with a risk-based framework that strengthens data quality, traceability, compliance, and regulatory readiness.

What helps programs advance from development to commercial scale? Ulrike Bauer explores the role of platform flexibility, device readiness and tailored support. Watch now.

Oncology approvals move fast. Learn how experienced CRO publishing teams help sponsors navigate RTOR, Project Orbis, and complex global submissions with confidence.

Explore best practices for comparator selection and supply optimization in clinical trials, including sourcing strategies, risk mitigation, regulatory compliance, and real-world cost-saving case studies.

Embedded, flexible clinical services model that scales sponsor capacity, standardizes quality delivery, and accelerates clinical development while sponsors retain strategic and operational control.

Explore how experienced teams, strategic site partnerships, and comprehensive research capabilities can help streamline complex organ impairment studies and support high-quality outcomes.

We know that functional outsourcing is vital to clinical development today. This is why we build relationships and communicate with you to develop effective solutions.

Explore how a next-generation RTSM approach can help CROs scale delivery, improve predictability, and support efficient trial execution across diverse sponsor portfolios.

Join us to see how HEOR drives impact across the global healthcare landscape.

An Institutional Review Board protects human research participants by evaluating study ethics, consent, and risks, while providing sponsors with ongoing guidance on complex trial protocols.

A strong molecule is no longer enough. Learn how trial strategy and operational readiness can help your cancer therapy reach patients faster.

AI in clinical research poses governance challenges. Clear ownership, consistent policies, and aligned teams help manage risk, ensure compliance, and drive responsible innovation in complex trials.

Proper planning for first-in-human studies is crucial to successful drug development, which requires innovative trial designs and sound CMC strategies to mitigate risk and expedite proof-of-concept.

Some drugs reach approval in 3–5 years instead of 8–10. Learn which scientific, regulatory, and operational conditions can help your program cut avoidable delay.